Page 22«..10..21222324..3040..»

Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Ms. S. Mishima Gerhart as Chief Regulatory Officer. Ms. Gerhart will lead the Company’s regulatory and quality strategies and activities.

The rest is here:
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

To Read More: Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
categoriaGlobal News Feed commentoComments Off on Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer | dataOctober 16th, 2023
Read All

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

By Dr. Matthew Watson

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five presentations and one poster at the 14th Annual World ADC Conference, taking place in San Diego, October 16-19, 2023.

View post:
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

To Read More: Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference
categoriaGlobal News Feed commentoComments Off on Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference | dataOctober 16th, 2023
Read All

PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

By Dr. Matthew Watson

SAN JOSE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2023 after market close on Wednesday, November 1, 2023. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Visit link:
PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023

To Read More: PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023
categoriaGlobal News Feed commentoComments Off on PROCEPT BioRobotics to Report Third Quarter 2023 Financial Results on November 1, 2023 | dataOctober 16th, 2023
Read All

Zymeworks Announces New Director Nominee

By Dr. Matthew Watson

VANCOUVER, British Columbia, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today announced that its board of directors will nominate Dr. Nancy Davidson for election to its board of directors at the Company’s upcoming annual general meeting of stockholders to be held on December 7, 2023.

Read more here:
Zymeworks Announces New Director Nominee

To Read More: Zymeworks Announces New Director Nominee
categoriaGlobal News Feed commentoComments Off on Zymeworks Announces New Director Nominee | dataOctober 16th, 2023
Read All

Titan Pharmaceuticals Announces Appointment of Dato’ Seow Gim Shen and Brynner Chaim to the Company’s Board of Directors

By Dr. Matthew Watson

SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato’ Seow Gim Shen and Brynner Chiam to the Company’s Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board.

Originally posted here:
Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

To Read More: Titan Pharmaceuticals Announces Appointment of Dato’ Seow Gim Shen and Brynner Chaim to the Company’s Board of Directors
categoriaGlobal News Feed commentoComments Off on Titan Pharmaceuticals Announces Appointment of Dato’ Seow Gim Shen and Brynner Chaim to the Company’s Board of Directors | dataOctober 16th, 2023
Read All

Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

By Dr. Matthew Watson

ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3

Follow this link:
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

To Read More: Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
categoriaGlobal News Feed commentoComments Off on Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey | dataOctober 16th, 2023
Read All

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

By Dr. Matthew Watson

FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that two abstracts detailing vebreltinib data were made available as part of the European Society of Medical Oncology Congress (ESMO) 2023 being held in Madrid, Spain from October 20-24, 2023.

Visit link:
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

To Read More: Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
categoriaGlobal News Feed commentoComments Off on Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023 | dataOctober 16th, 2023
Read All

Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of…

By daniellenierenberg

Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA  Marketscreener.com

Read this article:
Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of...

To Read More: Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of…
categoriaBone Marrow Stem Cells commentoComments Off on Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of… | dataMay 16th, 2023
Read All

Defence Mechanisms: Four ways your body is protecting you every time you fall sick – indulgexpress

By daniellenierenberg

Defence Mechanisms: Four ways your body is protecting you every time you fall sick  indulgexpress

See the rest here:
Defence Mechanisms: Four ways your body is protecting you every time you fall sick - indulgexpress

To Read More: Defence Mechanisms: Four ways your body is protecting you every time you fall sick – indulgexpress
categoriaSkin Stem Cells commentoComments Off on Defence Mechanisms: Four ways your body is protecting you every time you fall sick – indulgexpress | dataMay 16th, 2023
Read All

Treat Yourself to a Spa Day With a $100 Deal on $600 Worth of Products From Elemis, 111SKIN, Nest & More – E! NEWS

By daniellenierenberg

Treat Yourself to a Spa Day With a $100 Deal on $600 Worth of Products From Elemis, 111SKIN, Nest & More  E! NEWS

Read more from the original source:
Treat Yourself to a Spa Day With a $100 Deal on $600 Worth of Products From Elemis, 111SKIN, Nest & More - E! NEWS

To Read More: Treat Yourself to a Spa Day With a $100 Deal on $600 Worth of Products From Elemis, 111SKIN, Nest & More – E! NEWS
categoriaSkin Stem Cells commentoComments Off on Treat Yourself to a Spa Day With a $100 Deal on $600 Worth of Products From Elemis, 111SKIN, Nest & More – E! NEWS | dataMay 16th, 2023
Read All

Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

By Dr. Matthew Watson

DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today reported financial results for the three months ended March 31, 2023 and provided a business update.

See the original post:
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations

To Read More: Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
categoriaGlobal News Feed commentoComments Off on Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations | dataMay 16th, 2023
Read All

Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights

By Dr. Matthew Watson

- Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 –

Link:
Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights

To Read More: Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights
categoriaGlobal News Feed commentoComments Off on Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights | dataMay 16th, 2023
Read All

Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update

By Dr. Matthew Watson

Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers Squibb collaboration

Visit link:
Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update

To Read More: Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update
categoriaGlobal News Feed commentoComments Off on Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update | dataMay 16th, 2023
Read All

PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023

By Dr. Matthew Watson

TARRYTOWN, NY, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today provided a business update and reported financial results for the first quarter 2023 ended March 31, 2023.

Excerpt from:
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023

To Read More: PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023
categoriaGlobal News Feed commentoComments Off on PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023 | dataMay 16th, 2023
Read All

Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results

By Dr. Matthew Watson

- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial -

Read more here:
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results

To Read More: Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results
categoriaGlobal News Feed commentoComments Off on Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results | dataMay 16th, 2023
Read All

Sanara MedTech Inc. Announces First Quarter 2023 Results

By Dr. Matthew Watson

FORT WORTH, TX, May 15, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter ended March 31, 2023.

Visit link:
Sanara MedTech Inc. Announces First Quarter 2023 Results

To Read More: Sanara MedTech Inc. Announces First Quarter 2023 Results
categoriaGlobal News Feed commentoComments Off on Sanara MedTech Inc. Announces First Quarter 2023 Results | dataMay 16th, 2023
Read All

OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

By Dr. Matthew Watson

ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 2023 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.

View post:
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

To Read More: OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
categoriaGlobal News Feed commentoComments Off on OpGen Reports First Quarter 2023 Financial Results and Provides Business Update | dataMay 16th, 2023
Read All

Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

By Dr. Matthew Watson

FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024 FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of January 3, 2024

Link:
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

To Read More: Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
categoriaGlobal News Feed commentoComments Off on Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights | dataMay 16th, 2023
Read All

Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

By Dr. Matthew Watson

Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for the potential treatment of Alport syndrome expected in first half of 2023; meaningful protein reduction has been observed in one patient to date

Link:
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

To Read More: Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
categoriaGlobal News Feed commentoComments Off on Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update | dataMay 16th, 2023
Read All

Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates

By Dr. Matthew Watson

WARRINGTON, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the first quarter ended March 31, 2023 and provided key business updates.

Go here to see the original:
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates

To Read More: Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
categoriaGlobal News Feed commentoComments Off on Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates | dataMay 16th, 2023
Read All

Page 22«..10..21222324..3040..»


Copyright :: 2024